Blenrep

News

Against the odds, GSK has secured FDA approval for its multiple myeloma therapy Blenrep, three years after it was removed from sale.

News

GSK has added the EMA to the list of regulatory bodies approving Blenrep for multiple myeloma, but whether the FDA is next is still an open question.

News

FDA advisors have voted that the benefit/risk profile of GSK's multiple myeloma therapy, Blenrep, does not support its approval in the US.

News

England is the first country in the world to make GSK's relaunched anti-BCMA drug Blenrep available to patients with multiple myeloma.

News

The CHMP backed approval of Autolus' leukaemia CAR-T Aucatzyl, as well as drugs from GSK, Roche, SpringWorks, and others, at its May meeting.

News

The revitalisation of GSK's blood cancer therapy Blenrep continues with a second approval, in Japan, as a second-line treatment for multiple myeloma.